These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
292 related articles for article (PubMed ID: 15074332)
1. Use of meglumine antimoniate in canine leishmaniasis. Lamothe J Vet Rec; 2004 Mar; 154(12):378. PubMed ID: 15074332 [No Abstract] [Full Text] [Related]
2. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis. Moosavi Z; Nakhli A; Rassaii S Int J Dermatol; 2005 Dec; 44(12):1064-5. PubMed ID: 16409282 [No Abstract] [Full Text] [Related]
3. Clinical follow-up examination after treatment of canine leishmaniasis. Moritz A; Steuber S; Greiner M Tokai J Exp Clin Med; 1998 Dec; 23(6):279-83. PubMed ID: 10622623 [TBL] [Abstract][Full Text] [Related]
4. [N-methyl glucamine antimoniate or Glucantime]. Rapp C; Simon F; Dordain ML Med Trop (Mars); 2000; 60(4):342-3. PubMed ID: 11436584 [No Abstract] [Full Text] [Related]
5. Canine leishmaniasis chemotherapy: dog's clinical condition and risk of Leishmania transmission. João A; Pereira MA; Cortes S; Santos-Gomes GM J Vet Med A Physiol Pathol Clin Med; 2006 Dec; 53(10):540-5. PubMed ID: 17105576 [TBL] [Abstract][Full Text] [Related]
6. Characterization of circulating lymphocyte subpopulations in canine leishmaniasis throughout treatment with antimonials and allopurinol. Miranda S; Martorell S; Costa M; Ferrer L; Ramis A Vet Parasitol; 2007 Mar; 144(3-4):251-60. PubMed ID: 17110042 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of cryotherapy versus intralesional meglumine antimoniate (glucantime) for treatment of cutaneous leishmaniasis in children. Layegh P; Pezeshkpoor F; Soruri AH; Naviafar P; Moghiman T Am J Trop Med Hyg; 2009 Feb; 80(2):172-5. PubMed ID: 19190206 [TBL] [Abstract][Full Text] [Related]
8. Comparison of intralesional meglumine antimoniate, cryotherapy and their combination in the treatment of cutaneous leishmaniasis. Salmanpour R; Razmavar MR; Abtahi N Int J Dermatol; 2006 Sep; 45(9):1115-6. PubMed ID: 16961529 [No Abstract] [Full Text] [Related]
9. First report of the use of meglumine antimoniate for treatment of canine leishmaniasis in a pregnant dog. Spada E; Proverbio D; Groppetti D; Perego R; Grieco V; Ferro E J Am Anim Hosp Assoc; 2011; 47(1):67-71. PubMed ID: 21164165 [TBL] [Abstract][Full Text] [Related]
10. [Canine leishmaniasis in Spain: data for the clinician]. Ferrer L Enferm Infecc Microbiol Clin; 1989; 7(6):293-5. PubMed ID: 2490443 [No Abstract] [Full Text] [Related]
11. Cutaneous lupoid leishmaniasis: a case report. Ferahbaş A; Mistik S; Utaş S; Yaman O; Canoz O; Doganay M; Aşçioglu O Cutis; 2006 Jan; 77(1):25-8; quiz 37-8. PubMed ID: 16475491 [TBL] [Abstract][Full Text] [Related]
12. Canine visceral leishmaniasis: comparison of in vitro leishmanicidal activity of marbofloxacin, meglumine antimoniate and sodium stibogluconate. Vouldoukis I; Rougier S; Dugas B; Pino P; Mazier D; Woehrlé F Vet Parasitol; 2006 Jan; 135(2):137-46. PubMed ID: 16242844 [TBL] [Abstract][Full Text] [Related]
13. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis. Andersen EM; Cruz-Saldarriaga M; Llanos-Cuentas A; Luz-Cjuno M; Echevarria J; Miranda-Verastegui C; Colina O; Berman JD Am J Trop Med Hyg; 2005 Feb; 72(2):133-7. PubMed ID: 15741547 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of renal and hepatic functions in dogs naturally infected by visceral leishmaniasis submitted to treatment with meglumine antimoniate. Ikeda-Garcia FA; Lopes RS; Ciarlini PC; Marques FJ; Lima VM; Perri SH; Feitosa MM Res Vet Sci; 2007 Aug; 83(1):105-8. PubMed ID: 17150234 [TBL] [Abstract][Full Text] [Related]
15. Effects of antimonial therapy for canine leishmaniasis on antibody titer. Amusategui I; Sainz A; Tesouro MA Ann N Y Acad Sci; 1998 Jun; 849():444-6. PubMed ID: 9668509 [No Abstract] [Full Text] [Related]
16. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major. Shazad B; Abbaszadeh B; Khamesipour A Eur J Dermatol; 2005; 15(2):85-7. PubMed ID: 15757817 [TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of two different drug combinations for the treatment of canine leishmaniasis. Pennisi MG; Lo Giudice S; Masucci M; De Majo M; Reale S; Vitale F Vet Res Commun; 2008 Sep; 32 Suppl 1():S303-5. PubMed ID: 18683068 [No Abstract] [Full Text] [Related]
18. Systemic Meglumine Antimoniate in Cutaneous Leishmaniasis of Children: Clinical and Laboratory Complications. Layegh P; Khademi Z; Afzal Aghaee M; Moghiman T J Pediatric Infect Dis Soc; 2015 Dec; 4(4):356-8. PubMed ID: 26582874 [TBL] [Abstract][Full Text] [Related]
19. Real-time PCR assay in Leishmania-infected dogs treated with meglumine antimoniate and allopurinol. Manna L; Reale S; Vitale F; Picillo E; Pavone LM; Gravino AE Vet J; 2008 Aug; 177(2):279-82. PubMed ID: 17553711 [TBL] [Abstract][Full Text] [Related]
20. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Mohebali M; Fotouhi A; Hooshmand B; Zarei Z; Akhoundi B; Rahnema A; Razaghian AR; Kabir MJ; Nadim A Acta Trop; 2007 Jul; 103(1):33-40. PubMed ID: 17586452 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]